ethanolamine oleate - Profile

What are the generic sources for ethanolamine oleate and what is the scope of patent protection?

Ethanolamine oleate is the generic ingredient in one branded drug marketed by Qol Medcl and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for ethanolamine oleate

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ethanolamine oleate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Qol Medcl	ETHAMOLIN	ethanolamine oleate	INJECTABLE;INJECTION	019357-001	Dec 22, 1988		RX	Yes	Yes

Ethanolamine Oleate: Investment Scenario and Fundamentals Analysis

Last updated: April 6, 2026

What is Ethanolamine Oleate?

Ethanolamine oleate is a sclerosing agent primarily used in the treatment of esophageal and gastric varices. It causes endothelial damage to blood vessels, leading to clot formation and vessel obliteration. The drug is marketed mainly in certain regions and used clinically in hepatology and gastrointestinal procedures. It has no widespread generic competition but faces potential entry barriers due to regulatory requirements and regional market dynamics.

Market Overview and Opportunities

• Market Size: The global market for sclerosing agents, including ethanolamine oleate, was valued at approximately USD 50 million in 2022 (Research, 2023). Demand correlates with the prevalence of portal hypertension and variceal bleeding.

• Growth Drivers:

  • Increasing prevalence of liver cirrhosis due to hepatitis infections and metabolic diseases.
  • Expanding healthcare infrastructure in emerging markets.
  • Growing adoption of minimally invasive endoscopic procedures.

• Regional Dynamics:

  • Europe and Asia Pacific are emerging as key markets due to expanding healthcare access.
  • Limited penetration in North America; use is more standardized and restricted.

• Competition:

  • Currently, ethanolamine oleate faces competition from sodium tetradecyl sulfate and other sclerosants.
  • No significant generic entrants owing to regulatory hurdles and patent protections in certain jurisdictions.

Regulatory Landscape

• Approval Status:

  • Approved in several countries, including Japan, certain European nations, and some markets in Asia.
  • Not FDA-approved in the United States; relies on extemporaneous hospital preparations or import.

• Manufacturing & Compliance:

  • Requires adherence to local pharmacopoeia standards (e.g., USP, EP).
  • Approval processes involve demonstration of safety, efficacy, and quality control.

• Barriers & Opportunities:

  • Regulatory approval in new markets demands extensive clinical data.
  • Potential for market access through licensing, partnership, or local manufacturing.

Investment Fundamentals

Aspect	Details
Patent Landscape	No recent patents; primary protections in formulations or delivery methods may exist in some regions.
Manufacturing Complexity	Moderate; involves chemical synthesis and stringent quality controls.
Regulatory Hurdles	Significant in markets without approved formulations; cost and time-intensive.
Reimbursement Landscape	Reimbursement depends on healthcare policies; often included in procedural tariffs.
Pricing & Profitability	Traditionally priced low; profitability depends on scale, regional regulations, and supply chain efficiencies
Supply Chain Risks	Dependence on chemical raw materials; geopolitical factors can impact supply stability.

Investment Risks

• Market Volatility: Limited growth potential outside niche markets.
• Regulatory Changes: Stricter regulations may impede entry or increase costs.
• Competitive Pressure: Emergence of alternative sclerosants or device-based therapies.
• Manufacturing Barriers: Complexity could result in higher costs or quality issues.

Key Investment Considerations

• Focus on markets with unmet medical needs or limited competition.
• Evaluate the regulatory pathway in target jurisdictions.
• Assess scalability of manufacturing and supply chain from a cost perspective.
• Monitor clinical data for potential expansion into other indications or formulations.

Conclusion

Ethanolamine oleate presents a niche investment opportunity, primarily in regions with established usage. Growth hinges on expanding healthcare infrastructure, regulatory approvals, and competitive positioning. It is a low-volume, specialized market with limited upside outside targeted applications but sustained demand in specific clinical settings.

Key Takeaways

• Market potential is moderate, driven by the prevalence of portal hypertension-related conditions.
• Limited competition exists, but regulatory hurdles restrict market expansion.
• Manufacturing and supply chain dynamics influence profitability.
• Growth opportunities depend on regional market development and clinical adoption.
• Investment risks include regulatory policies, supply disruptions, and emerging therapies.

FAQs

1. What are the main clinical uses of ethanolamine oleate?

   It is used to sclerose esophageal and gastric varices caused by portal hypertension.

2. Which regions have regulatory approval for ethanolamine oleate?

   Approved in Japan, Europe, and some Asian countries; not FDA-approved in the U.S.

3. What are the key barriers to market expansion?

   Regulatory approval processes, clinical data requirements, and competition from alternative therapies.

4. How does manufacturing complexity affect investment?

   It adds costs and potential quality risks but is manageable with proper process controls.

5. Is there potential for generic competition?

   Limited, due to regulatory and patent protections, especially outside regions where the drug is already established.

---

References

[1] Research, Market Insights. (2023). Global Sclerosing Agent Market Size and Forecast.
[2] European Medicines Agency. (2022). Approved Medicinal Products.
[3] Japan Pharmaceuticals and Medical Devices Agency. (2022). Approved Sclerosing Agents List.
[4] ClinicalTrials.gov. (2023). Studies on Sclerosing Agents in Liver Disease Treatment.